Biospecimen: * 1 or 2 tumoral specimen (depending on the size of the tumor).
* 1 specimen of the healthy oral mucosa.
* 1 OPMD specimen if applicable. The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.
Blood sampling: Blood sampling (6 mL), taken from a routine biological exam.
Biospecimen: * 1 OPMD lesion specimen.
* 1 specimen of the healthy oral mucosa (facultative). The biospecimens will be collected during standard routine medical care.
Biospecimen: * 1 cytobrush sample.
* 1 OPMD lesion specimen. Samples must be collected in sequence (first the cytobrush, then the biopsy collected during standard routine medical care.).
Study summary
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* I1: Male or female at least 18 years old.
* I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD.
* I3: Patient who has agreed to participate in this research and sign consent.
* I4: Patient affiliated to a medical insurance.
* I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy)
Exclusion Criteria:
* NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment.
* NI2: Pregnant or nursing woman.
* NI3: Contraindication to general anesthesia.
* NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).
* NI5: Patient under curatorial or guardianship or placed under the protection of justice.
Primary outcome measure(s)
Characterization of the heterogeneity of all cell populations (tumor cells, stromal and immune microenvironment) in OSCC and OPMD using scRNA-seq. — 4 years Evaluation of transcriptomic data from all cell populations to define gene expression profiles and specific signatures.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.